title: Induced pluripotent stem cells: the new patient?
abstract: Worldwide increases in life expectancy have been paralleled by a greater prevalence of chronic and age-associated disorders, particularly of the cardiovascular, neural and metabolic systems. This has not been met by commensurate development of new drugs and therapies, which is in part owing to the difficulty in modelling human diseases in laboratory assays or experimental animals. Patient-specific induced pluripotent stem (iPS) cells are an emerging paradigm that may address this. Reprogrammed somatic cells from patients are already applied in disease modelling, drug testing and drug discovery, thus enabling researchers to undertake studies for treating diseases 'in a dish', which was previously inconceivable.
authors.affiliation: Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Milena
authors.initials: M
authors.lastname: Bellin
authors.forename: Maria C
authors.initials: MC
authors.lastname: Marchetto
authors.forename: Fred H
authors.initials: FH
authors.lastname: Gage
authors.forename: Christine L
authors.initials: CL
authors.lastname: Mummery
mesh_terms: D000375:Aging; D000818:Animals; D057005:Bioengineering; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000628:therapy; D002454:Cell Differentiation; D002478:Cells, Cultured; D055808:Drug Discovery; D006801:Humans; D057026:Induced Pluripotent Stem Cells; D008659:Metabolic Diseases / Q000503:physiopathology / Q000628:therapy; D008954:Models, Biological; D032383:Myocytes, Cardiac / Q000502:physiology; D019636:Neurodegenerative Diseases / Q000503:physiopathology / Q000628:therapy; D009474:Neurons / Q000502:physiology